Orally bioavailable, high molecular weight macrocyclic peptides that inhibit difficult-to-drug protein–protein interactions are of high therapeutic value, and rules for their design were proposed recently. Here, we emphasize the danger of rules that provide a false impression of the lipophilicity required of a clinical candidate.

中文翻译：

---

设计环肽时要注意极端计算的亲脂性


口服生物可利用的高分子量大环肽可抑制难以药物的蛋白质-蛋白质相互作用，具有很高的治疗价值，最近提出了其设计规则。在这里，我们强调规则的危险性，这些规则对临床候选人所需的亲脂性产生了错误的印象。